Lee Discusses Results From KEYNOTE-146 Trial of Lenvatinib Plus Pembrolizumab

Video

Chung-Han Lee, MD, PhD, spoke about interesting findings that arose from the KEYNOTE-146 study for patients with metastatic renal cell carcinoma.

In an interview with CancerNetwork® during the 2022 Genitourinary Cancers Symposium,Chung-Han Lee, MD, PhD, assistant attending physician for the Genitourinary Oncology service at Memorial Sloan Kettering Cancer Center in New York City, discussed results of the KEYNOTE-146 study (NCT02501096) of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) in patients with metastatic renal cell carcinoma (RCC).

Transcript:

The KEYNOTE-146 study was a phase 1b/2 trial with multiple cohorts. Initially in the phase 1b portion, they [performed] dose finding of lenvatinib plus pembrolizumab in multiple different disease groups. This was later expanded to an RCC-specific cohort, looking at the efficacy of the regimen for people with clear cell kidney cancer. The initial design involved up to 2 prior systemic therapies, and all patients had to be treatment naive or IO [immuno-oncology] naïve. Later, they expanded this clinical trial to look specifically at patients who were previously treated with various IO systemic therapies.

We were able to demonstrate that the activity of this regimen still remains quite high. We were seeing this in multiple settings, [such as] high levels of activity in patients who are treatment naïve, in patients who’ve gotten TKI [tyrosine kinase inhibitor], and in people who are IO pretreated. The best indication of any predictive biomarkers has been quite limited. Right now, we’re seeing this across the board, which certainly surprised us. This is very encouraging from a patient perspective that, regardless of what type of patient they are, we’re still seeing great outcomes.

Reference

Lee CH, Rasco D, Rao A, et al. Association between biomarkers and clinical outcomes of lenvatinib + pembrolizumab in advanced renal cell carcinoma (RCC): Results from Study 111/KEYNOTE-146. J Clin Oncol. 2022;40(suppl 6):137. doi: 10.1200/JCO.2022.40.6_suppl.375

Recent Videos
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Related Content